About: Lexatumumab     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FLexatumumab

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015.

AttributesValues
rdf:type
rdfs:label
  • لكساتوموماب (ar)
  • Lexatumumab (it)
  • Lexatumumab (en)
rdfs:comment
  • لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان. (ar)
  • Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015. (en)
  • Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. (it)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
ATC prefix
  • none (en)
c
CAS number
ChemSpiderID
  • none (en)
H
KEGG
  • D06611 (en)
n
O
s
source
  • u (en)
target
  • TRAIL-R2 (en)
type
  • mab (en)
UNII
Verifiedfields
  • changed (en)
verifiedrevid
Watchedfields
  • changed (en)
has abstract
  • لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان. (ar)
  • Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015. (en)
  • Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. (it)
mab type
  • mab (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • 845816-02-6
FDA UNII code
  • 967Q0SJD77
KEGG
  • D06611
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 38 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software